Innate Pharma SA (IPHA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Annual

0 20M 40M 60M 2021: 12.1M 2022: 49.6M 2023: 51.9M 2024: 12.6M 2025: 2.8M 2021 2022 2023 2024 2025

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-60M -40M -20M 0 20M 40M 60M 2021: -47.8M 2022: -57.4M 2023: -12.7M 2024: -51.6M 2025: -54M 2021 2022 2023 2024 2025

Net Income Annual

-60M -40M -20M 0 20M 40M 60M 2021: -52.8M 2022: -58.1M 2023: -7.6M 2024: -49.5M 2025: -49.2M 2021 2022 2023 2024 2025

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M 2021: -58.5M 2022: -19.2M 2023: -32.6M 2024: -6.9M 2025: -52.8M 2021 2022 2023 2024 2025

Free Cash Flow Annual

-75M -50M -25M 0 25M 50M 75M 2021: -59.4M 2022: -19.7M 2023: -32.9M 2024: -7.3M 2025: -52.9M 2021 2022 2023 2024 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 35M 70M 105M 2021: 79.5M 2022: 79.6M 2023: 80.5M 2024: 81.1M 2025: 89.6M 2021 2022 2023 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.